SNBIF
Price
$16.45
Change
+$2.17 (+15.20%)
Updated
Aug 6 closing price
Capitalization
1.72B
Intraday Buy/Sell Signals
SPHRY
Price
$1.91
Change
-$0.10 (-4.98%)
Updated
Oct 10 closing price
Capitalization
73.37M
27 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

SNBIF vs SPHRY

Header iconSNBIF vs SPHRY Comparison
Open Charts SNBIF vs SPHRYBanner chart's image
Sanbio
Price$16.45
Change+$2.17 (+15.20%)
Volume$500
Capitalization1.72B
Starpharma Holdings
Price$1.91
Change-$0.10 (-4.98%)
Volume$200
Capitalization73.37M
SNBIF vs SPHRY Comparison Chart in %
SNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SNBIF vs. SPHRY commentary
Oct 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SNBIF is a Buy and SPHRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 15, 2025
Stock price -- (SNBIF: $16.45 vs. SPHRY: $1.91)
Brand notoriety: SNBIF and SPHRY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SNBIF: 100% vs. SPHRY: 6%
Market capitalization -- SNBIF: $1.82B vs. SPHRY: $70.39M
SNBIF [@Biotechnology] is valued at $1.82B. SPHRY’s [@Biotechnology] market capitalization is $70.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $104.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SNBIF’s FA Score shows that 0 FA rating(s) are green whileSPHRY’s FA Score has 0 green FA rating(s).

  • SNBIF’s FA Score: 0 green, 5 red.
  • SPHRY’s FA Score: 0 green, 5 red.
According to our system of comparison, SPHRY is a better buy in the long-term than SNBIF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SNBIF’s TA Score shows that 1 TA indicator(s) are bullish while SPHRY’s TA Score has 4 bullish TA indicator(s).

  • SNBIF’s TA Score: 1 bullish, 0 bearish.
  • SPHRY’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both SNBIF and SPHRY are a good buy in the short-term.

Price Growth

SNBIF (@Biotechnology) experienced а 0.00% price change this week, while SPHRY (@Biotechnology) price change was -9.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.86%. For the same industry, the average monthly price growth was +14.21%, and the average quarterly price growth was +268.76%.

Reported Earning Dates

SPHRY is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+0.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNBIF($1.72B) has a higher market cap than SPHRY($73.4M). SNBIF YTD gains are higher at: 253.763 vs. SPHRY (196.907). SPHRY has higher annual earnings (EBITDA): -13.7M vs. SNBIF (-4.28B). SPHRY has higher revenues than SNBIF: SPHRY (2.98M) vs SNBIF (0).
SNBIFSPHRYSNBIF / SPHRY
Capitalization1.72B73.4M2,346%
EBITDA-4.28B-13.7M31,218%
Gain YTD253.763196.907129%
P/E RatioN/AN/A-
Revenue02.98M-
Total Cash2.74BN/A-
Total Debt1.36BN/A-
FUNDAMENTALS RATINGS
SNBIF vs SPHRY: Fundamental Ratings
SNBIF
SPHRY
OUTLOOK RATING
1..100
4783
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
44
Fair valued
PROFIT vs RISK RATING
1..100
85100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
3534
P/E GROWTH RATING
1..100
66100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPHRY's Valuation (44) in the null industry is somewhat better than the same rating for SNBIF (95). This means that SPHRY’s stock grew somewhat faster than SNBIF’s over the last 12 months.

SNBIF's Profit vs Risk Rating (85) in the null industry is in the same range as SPHRY (100). This means that SNBIF’s stock grew similarly to SPHRY’s over the last 12 months.

SPHRY's SMR Rating (97) in the null industry is in the same range as SNBIF (99). This means that SPHRY’s stock grew similarly to SNBIF’s over the last 12 months.

SPHRY's Price Growth Rating (34) in the null industry is in the same range as SNBIF (35). This means that SPHRY’s stock grew similarly to SNBIF’s over the last 12 months.

SNBIF's P/E Growth Rating (66) in the null industry is somewhat better than the same rating for SPHRY (100). This means that SNBIF’s stock grew somewhat faster than SPHRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SNBIFSPHRY
RSI
ODDS (%)
N/A
Bearish Trend 7 days ago
82%
Stochastic
ODDS (%)
N/A
Bearish Trend 7 days ago
86%
Momentum
ODDS (%)
N/A
Bullish Trend 7 days ago
63%
MACD
ODDS (%)
N/A
Bullish Trend 7 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
13%
Bullish Trend 7 days ago
62%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
9%
Bullish Trend 7 days ago
57%
Advances
ODDS (%)
N/A
Bullish Trend 12 days ago
63%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 7 days ago
88%
Aroon
ODDS (%)
Bullish Trend 7 days ago
41%
Bullish Trend 7 days ago
46%
View a ticker or compare two or three
Interact to see
Advertisement
SNBIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NNUP1.630.08
+5.16%
Nocopi Technologies, Inc.
APXYY0.220.01
+3.83%
Appen Ltd.
EADSY59.170.69
+1.18%
Airbus SE
WRFRF2.88N/A
N/A
Wharf Real Estate Investment Co Ltd.
MXCHY1.68N/A
N/A
Orbia Advance Corp S A B

SNBIF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNBIF has been loosely correlated with AZTR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SNBIF jumps, then AZTR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNBIF
1D Price
Change %
SNBIF100%
N/A
AZTR - SNBIF
46%
Loosely correlated
+8.85%
ANTX - SNBIF
33%
Loosely correlated
-1.59%
SONN - SNBIF
28%
Poorly correlated
-1.37%
RZLT - SNBIF
5%
Poorly correlated
+4.34%
SPHRY - SNBIF
3%
Poorly correlated
N/A
More

SPHRY and

Correlation & Price change

A.I.dvisor tells us that SPHRY and VACBF have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SPHRY and VACBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHRY
1D Price
Change %
SPHRY100%
N/A
VACBF - SPHRY
26%
Poorly correlated
N/A
SPHRF - SPHRY
26%
Poorly correlated
N/A
REVB - SPHRY
23%
Poorly correlated
+1.49%
ZBIO - SPHRY
22%
Poorly correlated
-2.60%
INM - SPHRY
21%
Poorly correlated
+3.29%
More